Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 3;11(11):947. doi: 10.1038/s41419-020-03155-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — a AS101 (1 mg/kg) was intraperitoneal injected, and 10 μL antagomir of miR-18a (250 nM) were intra-articular injected in rat model of knee OA every 3 days, followed by dissociation of knee joint after 4 weeks. HE staining, Safarin O, and fast green staining, and IHC of p65, p-SMAD2/3, and RUNX2 were conducted. Scale bar: 50 μm. b Mankin’s score was assessed. c Expression of SERPINE1 and RUNX2 in articular cartilage from OA rats with administration of AS101 or combination of AS101 and miR-18a antagomir. d qRT-PCR to determine the expression of hypertrophy-related genes in human ACs and SW1353 cells with treatment of adalimumab or combination of adalimumab and miR-18a antagomir. Data in b–d are presented as mean ± SD. *P < 0.05.